Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück zu finanzen.net geht es hier.
SMI 10’896 -0.1%  SPI 14’023 -0.2%  Dow 31’438 -0.2%  DAX 13’292 0.8%  Euro 1.0106 -0.1%  EStoxx50 3’569 0.8%  Gold 1’828 0.3%  Bitcoin 19’948 0.6%  Dollar 0.9545 -0.2%  Öl 116.7 1.0% 

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
18.05.2022 17:53:00

Why Pfizer Looks Better Than Moderna as a Long-Term Buy

For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. COVID-19 stocks that did well during the early stages of the pandemic may have questionable futures heading into next year as concerns around the pandemic subside.Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. And while both businesses are doing well of late, Pfizer is the one that stands out to me as the better stock for long-term investors. Here's why.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

BITCOIN KURSZIEL 100'000 US-DOLLAR? WELCHER COIN KÖNNTE DER NÄCHSTE VERDOPPLER SEIN?

Informieren Sie sich aus erster Hand über Nachrichten, die Krypto-Kurse bewegen. Abonnieren Sie jetzt kostenlos unseren neuen Krypto-Newsletter!